Opdivo (nivolumab) in combination with Yervoy (ipilimumab) newly approved first-line treatment of adults with malignant pleural mesothelioma.
5 Ottobre 2020
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma
